In glioblastoma, oroxylin A was observed to promote VHL-mediated HIF-1α degradation and limit the HIF-1α-Hh signaling pathway, thus sensitizing glioma cells to temozolomide in vitro and in vivo [85]. This evidence concerns the gene HIF1A and glioblastoma.